N/A N=43 The Diet Gout Trial
Gout · Hyperuricemia
Primary: Uric Acid Level — 8.23; 8.03 mg/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=399 Colchicine Or Naproxen Treatment for ACute gouT
Gout
Primary: Change in Pain Intensity — 3.5; 3.8 units on a scale
N/A N=1,463 Virtual Gout Clinic
Gout
Primary: sUA < 6.0 mg/dl at 1 Year — 117; 204 Participants
N/A N=60 Gout Self-Monitoring Aiming to Reach Target
Gout
Primary: Percentage of Participants Achieving Target Urate Levels (24 Weeks) — 29; 3 Participants
Phase 4 N=74 An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.
Gout
Primary: Number and Percentage of Participants With Evidence of Chronic Ongoing Synovial-Based Inflammatory Disease at Baseline. — 63 Participants — p=0.34
Phase 2 N=37 Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout
Gout
Primary: Reduction in Plasma Uric Acid to Less Than 6 mg/dL. — 17 Participants
Phase 3 N=225 Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout
Gout
Primary: Plasma Uric Acid (PUA) Responder — 36; 29; 0 Participants — p=<0.001
Phase 2 N=314 Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout
Joint Damage
Primary: Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Score of the Single Affected Joint — 0.16; 0.11; 0.01; 0.01 score on a scale — p=0.472
Phase 3 N=402 Celebrex In Acute Gouty Arthritis Study
Arthritis, Gouty
Primary: Change From Baseline to Day 2 in Patient's Assessment of Pain Intensity — 3.03; 2.73; 2.84; 2.83 Scores on a scale
Phase 2 N=82 A Proof-of-Concept Study of AC-201 to Prevent Gout Flares
Gout Flares
Primary: Number of Gout Flares Per Subject — 3.02; 2.45 flares — p=0.1356
Phase 4 N=940 CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat
Gout · Chronic Kidney Diseases
Primary: Percentage of Participants Experiencing ≥ 1 Gout Flare During Phase 3 — 135; 165 Participants — p=<0.001
Phase 3 N=248 PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)
Gout
Primary: Number of Gout Flares Per Participant Assessed From Day 1 to Day 113 (Week 16) — 1.23; 0.35; 0.34 Gout flares
Phase 2 N=143 A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia
Gout · Hyperuricemia
Primary: Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84 — 47.1; 44.7; 62.2; 2.9 Percentage of participants
Phase 2 N=127 A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout
Gout
Primary: Proportion of Subjects Achieving Serum Uric Acid Concentration <6.0 mg/dL — 33; 43 Participants
Phase 3 N=185 MPC-004 for the Treatment of an Acute Gout Flare
Gout
Primary: Responders — 17; 28; 9 Participants
Phase 3 N=451 A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout
Gout
Primary: Percentage of Participants With Serum Uric Acid (SUA) Level <=6.0 mg/dL at Week 24 (LOCF) — 38.1; 73.6 percentage of participants — p=<0.001
Phase 2 N=153 Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout
Gout
Primary: Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 Milligram Per Deciliter (mg/dL) at the Day 28 Visit. — 56; 76; 94; 0 percentage of subjects — p=<0.001
Phase 3 N=241 PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1
Intercritical Gout
Primary: Number of Gout Flares Per Participant Assessed From Day 1 to Day 112 (Week 16) — 1.06; 0.29; 0.21 Number of Gout flares per participant
Phase 3 N=1,315 Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)
Gout
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 59.1; 66.6; 13.0; 27.5 percentage of participants
N/A N=32 Magnetic Resonance Imaging in Subjects With Gouty Tophi
Hyperuricemia · Gout
Primary: Measurement of Tophi by MRI - Difference in Volument Between Visits — -0.05 centimeters³ (cm³) — p=0.785
N/A N=44 Novel Methods for Ascertainment of Gout Flares -A Pilot Study
Gout
Primary: Preference IVR vs RheumPRO — 3; 28 Participants
Phase 4 N=1,732 Allopurinol Outcome Study
Gout
Primary: Safety of Allopurinol — 55.1 percentage of subjects
Phase 2 N=83 Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares
Gout
Primary: Number of Gout Flares Per Participant Assessed From Day 1 to Day 84 (Week 12) — 0.79; 0.15 Number of gout flares per participant
Phase 2 N=20 Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions
Gout
Primary: CT Bone Erosion Score — 6.6; 7.0 Score on a scale
Phase 3 N=1,072 Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.
Gout
Primary: Percentage of Subjects Whose Last Three Serum Urate Levels Are <6.0 Milligram Per Deciliter (mg/dL). — 48; 65; 69; 22 Percentage of subjects — p=<0.001
Phase 3 N=2,269 Efficacy and Safety of Oral Febuxostat in Participants With Gout
Gout
Primary: Percentage of Subjects Whose Serum Urate Level is <6.0 Milligrams Per Deciliter (mg/dL) at the Final Visit. — 45.2; 67.1; 42.1 percentage of subjects — p=0.233
Phase 2 N=152 Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid
Gout Chronic · Hyperuricemia
Primary: Safety and Tolerability of Multiple Intravenous Infusions of SEL-037 or SEL-212 as Assessed by the Percentage of Participants Experiencing Serious Adverse Events and…
Phase 3 N=225 Study Utilizing Rilonacept in Gout Exacerbations
Acute Gout Flare
Primary: Change From Baseline in Patient's Assessment of Pain Using a 5-Point Likert Scale (PAP-LS) in Index Joint to Averaged PAP-LS at 24, 48 and 72 Hours — -1.40; -1.55; -0.69…
Phase 2 N=96 Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
Renal Impairment
Primary: Change From Baseline to Month 12 in Serum Creatinine — 2.52; 2.10; 2.22; 0.19 mg/dL — p=0.459
Phase 2 N=64 RDEA3170 and Febuxostat Combination Study in Gout Subjects
Gout
Primary: Serum Urate Maximum Percentage (%) Change (Emax, CB) — -43.5; -55.6; -70.4; -79.1 Percentage (%) — p=<0.0001